Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer&#039;s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Wilcock, Gordon K; Gauthier, Serge; Frisoni, Giovanni; Jia, Jianping; Hardlund, Jiri H; Moebius, Hans J; Bentham, Peter; Kook, Karin A; Schelter, Bjoern O; Wischik, Damon J; Davis, Charles S; Staff, Roger T; Vuksanovic, Vesna; Ahearn, Trevor; Bracoud, Luc; Shamsi, Kohkan; Marek, Ken; Seibyl, John; Riedel, Gernot; Storey, John M D; Harrington, Charles R; Wischik, Claude M

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Authors		Wilcock, Gordon K Gauthier, Serge Frisoni, Giovanni Jia, Jianping Hardlund, Jiri H Moebius, Hans J Bentham, Peter Kook, Karin A Schelter, Bjoern O Wischik, Damon J Davis, Charles S Staff, Roger T Vuksanovic, Vesna Ahearn, Trevor Bracoud, Luc Shamsi, Kohkan Marek, Ken Seibyl, John Riedel, Gernot Storey, John M D Harrington, Charles R Wischik, Claude M show all authors [1 - 22]
Published in		Journal of Alzheimer's Disease. 2018, vol. 61, no. 1, p. 435-457
Abstract		LMTM is being developed as a treatment for AD based on inhibition of tau aggregation.
Keywords		Aged — Aged, 80 and over — Alzheimer Disease/diagnostic imaging/drug therapy — Antipsychotic Agents/therapeutic use — Cohort Studies — Double-Blind Method — Female — Humans — International Cooperation — Male — Mental Status and Dementia Tests — Methylene Blue/analogs & derivatives/therapeutic use — Middle Aged — Treatment Outcome
Identifiers		DOI: 10.3233/JAD-170560 PMID: 29154277
Full text		Article (Published version) (1.7 MB) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie
Research group		Troubles de mémoire et maladie d'Alzeimer (935)
Citation (ISO format)		WILCOCK, Gordon K et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. In: Journal of Alzheimer's Disease, 2018, vol. 61, n° 1, p. 435-457. https://archive-ouverte.unige.ch/unige:116075